Winter, A. M., Scordo, M., Houillier, C., Illerhaus, G., Vasconcelos, A., DeStefano, J., Bernasconi, D., Cheng, Z., Bize, V., Houot, R. (2026). Lisocabtagene maraleucel (liso-cel) as first-line (1L) therapy for transplant-ineligible patients (pt) with primary central nervous system lymphoma (PCNSL): The CAROLYN study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps7097